180 related articles for article (PubMed ID: 37989928)
1. Momelotinib: First Approval.
Keam SJ
Drugs; 2023 Dec; 83(18):1709-1715. PubMed ID: 37989928
[TBL] [Abstract][Full Text] [Related]
2. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.
Verstovsek S; Courby S; Griesshammer M; Mesa RA; Brachmann CB; Kawashima J; Maltzman JD; Shao L; Xin Y; Huang D; Bajel A
Leuk Res; 2017 Sep; 60():11-17. PubMed ID: 28622623
[TBL] [Abstract][Full Text] [Related]
4. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
6. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
7. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
8. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
Asshoff M; Petzer V; Warr MR; Haschka D; Tymoszuk P; Demetz E; Seifert M; Posch W; Nairz M; Maciejewski P; Fowles P; Burns CJ; Smith G; Wagner KU; Weiss G; Whitney JA; Theurl I
Blood; 2017 Mar; 129(13):1823-1830. PubMed ID: 28188131
[TBL] [Abstract][Full Text] [Related]
9. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
10. Pacritinib: First Approval.
Lamb YN
Drugs; 2022 May; 82(7):831-838. PubMed ID: 35567653
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
12. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
14. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
16. Momelotinib in myelofibrosis.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
[TBL] [Abstract][Full Text] [Related]
17. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Pardanani A; Laborde RR; Lasho TL; Finke C; Begna K; Al-Kali A; Hogan WJ; Litzow MR; Leontovich A; Kowalski M; Tefferi A
Leukemia; 2013 Jun; 27(6):1322-7. PubMed ID: 23459451
[TBL] [Abstract][Full Text] [Related]
19. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Oh ST; Talpaz M; Gerds AT; Gupta V; Verstovsek S; Mesa R; Miller CB; Rivera CE; Fleischman AG; Goel S; Heaney ML; O'Connell C; Arcasoy MO; Zhang Y; Kawashima J; Ganz T; Kowalski M; Brachmann CB
Blood Adv; 2020 Sep; 4(18):4282-4291. PubMed ID: 32915978
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
